ARDELYX INC (ARDX)

US0396971071 - Common Stock

7.3  -0.11 (-1.48%)

After market: 7.29 -0.01 (-0.14%)

Fundamental Rating

3

Overall ARDX gets a fundamental rating of 3 out of 10. We evaluated ARDX against 592 industry peers in the Biotechnology industry. The financial health of ARDX is average, but there are quite some concerns on its profitability. ARDX shows excellent growth, but is valued quite expensive already.



2

1. Profitability

1.1 Basic Checks

In the past year ARDX has reported negative net income.
In the past year ARDX has reported a negative cash flow from operations.
In the past 5 years ARDX always reported negative net income.
ARDX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ARDX has a Return On Assets of -22.20%. This is in the better half of the industry: ARDX outperforms 78.91% of its industry peers.
With a decent Return On Equity value of -39.60%, ARDX is doing good in the industry, outperforming 75.00% of the companies in the same industry.
Industry RankSector Rank
ROA -22.2%
ROE -39.6%
ROIC N/A
ROA(3y)-54.36%
ROA(5y)-49.28%
ROE(3y)-99.82%
ROE(5y)-85.02%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 85.70%, ARDX belongs to the best of the industry, outperforming 89.80% of the companies in the same industry.
In the last couple of years the Gross Margin of ARDX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for ARDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.42%
GM growth 5Y0.89%

4

2. Health

2.1 Basic Checks

ARDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ARDX has been increased compared to 1 year ago.
The number of shares outstanding for ARDX has been increased compared to 5 years ago.
The debt/assets ratio for ARDX is higher compared to a year ago.

2.2 Solvency

ARDX has an Altman-Z score of 4.44. This indicates that ARDX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.44, ARDX is in the better half of the industry, outperforming 76.53% of the companies in the same industry.
ARDX has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.
ARDX's Debt to Equity ratio of 0.30 is on the low side compared to the rest of the industry. ARDX is outperformed by 71.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Altman-Z 4.44
ROIC/WACCN/A
WACC9.06%

2.3 Liquidity

ARDX has a Current Ratio of 4.88. This indicates that ARDX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.88, ARDX is in line with its industry, outperforming 51.53% of the companies in the same industry.
ARDX has a Quick Ratio of 4.64. This indicates that ARDX is financially healthy and has no problem in meeting its short term obligations.
ARDX has a Quick ratio (4.64) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.88
Quick Ratio 4.64

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 37.50% over the past year.
The Revenue has grown by 138.55% in the past year. This is a very strong growth!
The Revenue has been growing by 116.61% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)37.5%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-300%
Revenue 1Y (TTM)138.55%
Revenue growth 3Y154.28%
Revenue growth 5Y116.61%
Revenue growth Q2Q-22.22%

3.2 Future

The Earnings Per Share is expected to grow by 45.76% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 47.34% on average over the next years. This is a very strong growth
EPS Next Y-51.73%
EPS Next 2Y41.94%
EPS Next 3Y60.16%
EPS Next 5Y45.76%
Revenue Next Year68.52%
Revenue Next 2Y69.63%
Revenue Next 3Y64.22%
Revenue Next 5Y47.34%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

1

4. Valuation

4.1 Price/Earnings Ratio

ARDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ARDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

ARDX's earnings are expected to grow with 60.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.94%
EPS Next 3Y60.16%

0

5. Dividend

5.1 Amount

No dividends for ARDX!.
Industry RankSector Rank
Dividend Yield N/A

ARDELYX INC

NASDAQ:ARDX (3/28/2024, 7:31:49 PM)

After market: 7.29 -0.01 (-0.14%)

7.3

-0.11 (-1.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.70B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.2%
ROE -39.6%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 85.7%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.88
Quick Ratio 4.64
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)37.5%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-51.73%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)138.55%
Revenue growth 3Y154.28%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y